Celldex Therapeutics (CLDX) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $28.93, +3.92% vs the prior close of $27.84.
- Volume 1.18M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CLDX jumps 3.9% to $28.93. Closed at $28.93, +3.92% vs the prior close of $27.84. Day range $27.65–$28.95, opened at $28.05.
CLDX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CLDX jumps 3.9% to $28.93
- Closed at $28.93, +3.92% vs the prior close of $27.84. Day range $27.65–$28.95, opened at $28.05.
- Volume was 1.18M shares, 0.8x its 50-day average of 1.43M.
- Price is -21.5% vs its 50-day average ($36.87) and -11.0% vs its 200-day average ($32.49).
- 52-week range $22.10–$45.14; today's close sits at 30% of that range, 35.9% below the 52-week high.
Oct 14, 2026 — CLDX dips 1.5% to $27.84, a 6-month low, 3 down days in a row
- Closed at $27.84, -1.45% vs the prior close of $28.25. Day range $27.68–$28.73, opened at $28.49.
- Volume was 1.04M shares, 0.7x its 50-day average of 1.43M.
- Price is -25.0% vs its 50-day average ($37.12) and -14.3% vs its 200-day average ($32.48).
- 52-week range $22.10–$45.14; today's close sits at 25% of that range, 38.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CLDX slides 4.0% to $28.25, a 6-month low
- Closed at $28.25, -4.01% vs the prior close of $29.43. Day range $27.92–$29.28, opened at $29.28.
- Volume was 1.90M shares, 1.3x its 50-day average of 1.43M.
- Price is -24.3% vs its 50-day average ($37.34) and -13.0% vs its 200-day average ($32.47).
- 52-week range $22.10–$45.14; today's close sits at 27% of that range, 37.4% below the 52-week high.
Oct 12, 2026 — CLDX dips 1.5% to $29.43
- Closed at $29.43, -1.54% vs the prior close of $29.89. Day range $28.99–$30.03, opened at $29.61.
- Volume was 596.40K shares, 0.4x its 50-day average of 1.43M — lighter than usual.
- Price is -21.6% vs its 50-day average ($37.53) and -9.3% vs its 200-day average ($32.46).
- 52-week range $22.10–$45.14; today's close sits at 32% of that range, 34.8% below the 52-week high.
Oct 9, 2026 — CLDX rises 2.0% to $29.89
- Closed at $29.89, +2.01% vs the prior close of $29.30. Day range $28.88–$30.26, opened at $29.04.
- Volume was 992.70K shares, 0.7x its 50-day average of 1.43M.
- Price is -20.7% vs its 50-day average ($37.70) and -7.9% vs its 200-day average ($32.45).
- 52-week range $22.10–$45.14; today's close sits at 34% of that range, 33.8% below the 52-week high.
Oct 8, 2026 — CLDX slides 3.7% to $29.30, a 3-month low on 2.9x normal volume
- Closed at $29.30, -3.71% vs the prior close of $30.43. Day range $28.63–$30.10, opened at $30.07.
- Volume was 3.95M shares, 2.9x its 50-day average of 1.38M — unusually heavy trading.
- Price is -22.6% vs its 50-day average ($37.87) and -9.7% vs its 200-day average ($32.43).
- 52-week range $22.10–$45.14; today's close sits at 31% of that range, 35.1% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — CLDX dips 1.9% to $30.43, a 3-month low
- Closed at $30.43, -1.87% vs the prior close of $31.01. Day range $30.11–$31.35, opened at $30.62.
- Volume was 1.75M shares, 1.3x its 50-day average of 1.36M.
- Price is -20.0% vs its 50-day average ($38.04) and -6.1% vs its 200-day average ($32.42).
- 52-week range $22.10–$45.14; today's close sits at 36% of that range, 32.6% below the 52-week high.
Oct 6, 2026 — CLDX slides 4.8% to $31.01, a 3-month low
- Closed at $31.01, -4.85% vs the prior close of $32.59. Day range $30.85–$32.68, opened at $32.68.
- Volume was 1.77M shares, 1.3x its 50-day average of 1.34M.
- Price is -18.7% vs its 50-day average ($38.14) and -4.3% vs its 200-day average ($32.39).
- 52-week range $22.10–$45.14; today's close sits at 39% of that range, 31.3% below the 52-week high.
Oct 5, 2026 — CLDX rises 3.0% to $32.59
- Closed at $32.59, +2.97% vs the prior close of $31.65. Day range $31.50–$32.88, opened at $31.83.
- Volume was 1.26M shares, 0.9x its 50-day average of 1.33M.
- Price is -14.8% vs its 50-day average ($38.23) and +0.7% vs its 200-day average ($32.36).
- 52-week range $22.10–$45.14; today's close sits at 46% of that range, 27.8% below the 52-week high.
Oct 2, 2026 — CLDX dips 1.6% to $31.65 on 1.8x normal volume
- Closed at $31.65, -1.65% vs the prior close of $32.18. Day range $30.98–$32.54, opened at $32.26.
- Volume was 2.40M shares, 1.8x its 50-day average of 1.30M — unusually heavy trading.
- Price is -17.3% vs its 50-day average ($38.29) and -2.1% vs its 200-day average ($32.34).
- 52-week range $22.10–$45.14; today's close sits at 41% of that range, 29.9% below the 52-week high.
CLDX latest news & SEC filings
Every SEC filing by or about CLDX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 22, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $22.00K (prior year $730.00K) (-97.0% vs Jun 30, 2025)
- Net income: -$73.50M (prior year -$56.60M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.94 (prior year -$0.85) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 15, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jun 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 26, 2026 · S-8 — Registration of shares for employee stock plans (S-8)
Registration of shares for employee stock plans (S-8)
Jun 26, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade CLDX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 25, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.84% (largest 11.6%).
- Liquidity: about 2.44M shares (≈$70.47M) trade per day on average.
- 52-week position: $28.93 vs a range of $22.10–$45.14 (30% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 2 sales; latest: Freddy A. Jimenez sold 4,166 shares on Dec 4, 2025.
- Latest filings: 8-K Sep 22, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 78.53M shares outstanding (Jul 29, 2026), +18.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: In Vitro & In Vivo Diagnostic Substances.
CLDX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 28.05 | 28.95 | 27.65 | 28.93 | 1.18M |
| Oct 14, 2026 | 28.49 | 28.73 | 27.68 | 27.84 | 1.04M |
| Oct 13, 2026 | 29.28 | 29.28 | 27.92 | 28.25 | 1.90M |
| Oct 12, 2026 | 29.61 | 30.03 | 28.99 | 29.43 | 596.40K |
| Oct 9, 2026 | 29.04 | 30.26 | 28.88 | 29.89 | 992.70K |
| Oct 8, 2026 | 30.07 | 30.10 | 28.63 | 29.30 | 3.95M |
| Oct 7, 2026 | 30.62 | 31.35 | 30.11 | 30.43 | 1.75M |
| Oct 6, 2026 | 32.68 | 32.68 | 30.85 | 31.01 | 1.77M |
| Oct 5, 2026 | 31.83 | 32.88 | 31.50 | 32.59 | 1.26M |
| Oct 2, 2026 | 32.26 | 32.54 | 30.98 | 31.65 | 2.40M |
| Oct 1, 2026 | 32.26 | 32.55 | 31.70 | 32.18 | 1.44M |
| Sep 30, 2026 | 31.71 | 32.76 | 31.45 | 32.41 | 2.50M |
| Sep 29, 2026 | 31.49 | 31.79 | 31.00 | 31.64 | 2.03M |
| Sep 28, 2026 | 31.06 | 32.15 | 30.38 | 31.49 | 1.82M |
| Sep 25, 2026 | 31.48 | 31.71 | 30.65 | 31.10 | 2.02M |
| Sep 24, 2026 | 31.48 | 31.66 | 30.59 | 31.48 | 2.30M |
| Sep 23, 2026 | 33.54 | 33.59 | 30.41 | 31.12 | 4.24M |
| Sep 22, 2026 | 36.60 | 38.39 | 30.39 | 33.51 | 12.89M |
| Sep 21, 2026 | 41.62 | 41.62 | 37.48 | 37.89 | 549.50K |
| Sep 18, 2026 | 38.87 | 38.87 | 37.54 | 38.24 | 2.08M |
About Celldex Therapeutics
Celldex Therapeutics (CLDX) is listed on the Nasdaq and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in HAMPTON, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 744218.
CLDX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Keith L Brownlie | Director | Jun 29, 2026 |
| Herbert J Conrad | Director | Jun 29, 2026 |
| Cheryl Cohen | Director | Jun 29, 2026 |
| Rita Jain | Director | Jun 29, 2026 |
| James J Marino | Director | Jun 29, 2026 |
| Anthony S Marucci | PRESIDENT & CEO | Jun 29, 2026 |
| Garry Arthur Neil | Director | Jun 29, 2026 |
| Harry Jr Penner | Director | Jun 29, 2026 |
| Denice Torres | Director | Jun 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | Jun 29, 2026 |
| Elizabeth Crowley | SR. VP & CPDO | Jun 29, 2026 |
| Margo Heath-Chiozzi | SVP OF REGULATORY AFFAIRS | Jun 29, 2026 |
| Freddy A. Jimenez | SVP & GENERAL COUNSEL | Jun 29, 2026 |
| Tibor Keler | EXECUTIVE VP & CSO | Jun 29, 2026 |
| Teri L Lawver | SVP & Chief Commercial Officer | Jun 29, 2026 |
| Samuel Bates Martin | SVP AND CFO | Jun 29, 2026 |
| Anthony S Marucci | PRESIDENT & CEO | Jun 29, 2026 |
| Ronald Pepin | SR. VP & CBO | Jun 29, 2026 |
| Diane C. Young | SVP, CHIEF MEDICAL OFFICER | Jun 29, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Dec 4, 2025 | Freddy A. Jimenez | Sale | 4,166 | $29.10 |
| Nov 13, 2025 | Richard M. Wright | Sale | 49,298 | $24.00 |
CLDX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.54M | $-258.76M | -3.90 | $-210.94M |
| Dec 31, 2024 | $7.02M | $-157.86M | -2.45 | $-157.78M |
| Dec 31, 2023 | $6.88M | $-141.43M | -2.92 | $-107.29M |
| Dec 31, 2022 | $2.36M | — | -2.40 | $-103.73M |
| Dec 31, 2021 | $4.65M | — | -1.64 | $-60.91M |
Latest balance sheet: total assets $782.35M, total liabilities $67.78M, cash $47.45M (as of Jun 30, 2026).
CLDX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $41.56 |
| May 7, 2026 | 8-K Item 2.02 (results) | $33.32 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $30.82 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $22.67 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $21.21 |
| May 8, 2025 | 8-K Item 2.02 (results) | $19.52 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $20.31 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $27.63 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
| Feb 26, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories (IDXX)Lantheus (LNTH)Intellia Therapeutics (NTLA)Neogen (NEOG)QuidelOrtho (QDEL)Achieve Life Sciences (ACHV)Myriad Genetics (MYGN)Alpha Teknova (TKNO)Insight Molecular Diagnostics (IMDX)Volitionrx (VNRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CLDX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.